Ventricular pulsed field ablation from bench to bedside: preclinical and clinical evidence from a systematic review and meta-analysis
Europace · 02.09.2026 · 28 (9)
DOI: 10.1093/europace/euag221 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Europace, online erschienen am 19.08.2026. Verfasst von Paolo Compagnucci und 15 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology and Arrhythmology Clinic, University Hospital 'Azienda Ospedaliero-Universitaria Delle Marche', Via Conca 71, Ancona 60126, Italy. Hauptthemen laut MEDLINE: Tachycardia, Ventricular, Ventricular Premature Complexes, Heart Ventricles, Catheter Ablation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
Evidence supporting the use of pulsed field ablation (PFA) for ventricular arrhythmia (VA) ablation remains limited and heterogeneous, and the relationship between preclinical lesion characteristics and clinical outcomes is incompletely defined. We sought to systematically summarize preclinical lesion metrics and clinical outcomes of ventricular PFA. Methods and results We performed a systematic review and meta-analysis of preclinical and clinical studies of ventricular PFA. Preclinical studies reporting lesion depth or transmurality and clinical studies detailing procedural efficacy and safety were included. Random-effects models were used to pool lesion characteristics and clinical outcomes. Seventy-five studies were included (33 preclinical, 43 clinical; 355 patients). In preclinical models, mean lesion depth was 5.96 mm(95%CI, 5.07–6.84) in healthy endocardium and 5.19 mm (95%CI, 2.58–7.79) in healthy epicardium. Notably, lesion depth was quantitatively similar in models of scarred myocardium (5.96 mm; 95%CI, 5.39–6.53). Lesion transmurality was variable in healthy tissues (32%; 95%CI, 15–52%) but higher within scar (53%; 95%CI, 36–70%). Consistently, lesion depth was similar between PFA and RF in healthy myocardium, but greater with PFA in scarred models (within-study mean depth difference, 2.09 mm; 95%CI, 0.84–3.34). Greater contact force, repeated applications, and higher energy/duration settings were associated with increased lesion depth. Clinically, acute success was high for both premature ventricular complexes (PVCs,90%; 95%CI, 83–96%) and ventricular tachycardia (VT;92%; 95%CI, 87–96%) in studies with ≥3patients. Over a mean follow-up of approximately 5months, recurrence rates were 19% (95%CI, 12–28%) for PVCs and 21% (95%CI, 10–35%) for VT. The overall complication rate was 10% (95%CI, 5–17%) in studies with ≥3patients, with coronary artery spasm and conduction disturbances representing the most frequent adverse events.
Conclusion
Ventricular PFA demonstrates high acute efficacy and encouraging mid-term outcomes, supported by preclinical evidence of favourable lesion penetration within scarred myocardium. Safety considerations-particularly coronary and conduction system effects-and the heterogeneity of preclinical evidence highlight the need for further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiology and Arrhythmology Clinic, University Hospital 'Azienda Ospedaliero-Universitaria Delle Marche', Via Conca 71, Ancona 60126, Italy.
- Department of Biomedical Sciences and Public Health, Marche Polytechnic University, Ancona, Italy.
- Department of Clinical Sciences, Marche Polytechnic University, Ancona, Italy.
- IRCCS Maria Cecilia Hospital - GVM Care & Research, Cotignola, Italy.
- Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.
- Division of Cardiovascular Medicine, University of Chicago, Chicago, IL, USA.
ORCID-Profile: Paolo Compagnucci, Luca Finori, Michela Casella, Alessio Gasperetti, Yari Valeri, Leonardo D'Angelo, Francesca Campanelli, Giorgio Giacomini, Giovanni Volpato, Laura Cipolletta, Luigi Di Biase, Andrea Natale, Pasquale Santangeli, Antonio Dello Russo
Zitieren
APA
Compagnucci, P., Finori, L., Casella, M., Gasperetti, A., Huang, H. D., Valeri, Y., D'Angelo, L., Campanelli, F., Giacomini, G., Volpato, G., Cipolletta, L., Parisi, Q., Di Biase, L., Natale, A., Santangeli, P., & Dello Russo, A. (2026). Ventricular pulsed field ablation from bench to bedside: preclinical and clinical evidence from a systematic review and meta-analysis. Europace, 28(9). https://doi.org/10.1093/europace/euag221
Vancouver
Compagnucci P, Finori L, Casella M, Gasperetti A, Huang HD, Valeri Y, et al. Ventricular pulsed field ablation from bench to bedside: preclinical and clinical evidence from a systematic review and meta-analysis. Europace. 2026;28(9). doi:10.1093/europace/euag221
BibTeX
@article{Compagnucci2026,
author = {Compagnucci, Paolo and Finori, Luca and Casella, Michela and Gasperetti, Alessio and Huang, Henry D and Valeri, Yari and D'Angelo, Leonardo and Campanelli, Francesca and Giacomini, Giorgio and Volpato, Giovanni and Cipolletta, Laura and Parisi, Quintino and Di Biase, Luigi and Natale, Andrea and Santangeli, Pasquale and Dello Russo, Antonio},
title = {Ventricular pulsed field ablation from bench to bedside: preclinical and clinical evidence from a systematic review and meta-analysis},
journal = {Europace},
year = {2026},
volume = {28},
number = {9},
doi = {10.1093/europace/euag221}
}
EUVIMED